USA
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Firefly Neuroscience.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced advancing its artificial intelligence-powered Brain Network Analytics (BNA™) technology after successful research collaborations with Takeda Pharmaceutical Company Limited (“Takeda”) and Novartis, two global leaders in pharmaceutical R&D, illustrating the value of Firefly’s AI-based technology in providing objective measures in neuroscience drug development.
“Our collaborations with Takeda and Novartis mark a pivotal step in accelerating drug development,” said Jon Olsen, Firefly’s CEO. “By using our BNA™ technology, pharmaceutical companies can leverage the additional objective measures of brain activity to enhance the design of future trials and advance their drug candidates faster toward regulatory approval. Additionally, integrating Firefly's BNA™ technology into neuroscience drug development allows researchers to reduce costs and time by precisely measuring drug effects on the brain and identifying patients most likely to respond, leading to improved clinical outcomes.”
This is the News section of the company profile page for Firefly Neuroscience on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
